ENTITY
Celltrion Inc

Celltrion Inc (068270 KS)

641
Analysis
Health Care • South Korea
Celltrion Inc. produces and sells biosimilar products and also provides consignm ent processing service for other companies. The Company's main product is Abata cept which is for arthritis treatment
more
•05 Oct 2017 22:59

Foreign Investors Vs. Local Institutions in Korean Stock Market - Who Is Right?

Last month, foreign investors wentĀ on a buying spree in the Korea's second largest stock market, KOSDAQ. In contrast, they wentĀ on a selling spree...

Logo
1.2k Views
Share
bearish•Samsung Biologics
•04 Oct 2017 00:25

Biosimilar Battlefield: U.S. Humira Pushed to 2023

We are updating our market model to reflect the patent litigation settlement between Amgen Inc (AMGN US) and Abbvie Inc (ABBV US) ,Ā the...

Share
bullish•Celltrion Inc
•28 Sep 2017 22:05

Celltrion's KOSPI Move - Seo Jung-Jin, Temasek & Price Predictions

The big day (KOSPI move decision day) is tomorrow (Sep 29) for Celltrion Inc (068270 KS). At this point, many are thinking that Celltrion's KOSPI...

Logo
386 Views
Share
•25 Sep 2017 09:29

The Week That Was in NorthAsia@Smartkarma: Sep24

It has been another week in North Asia. North Korean missile/nuclear tests and threats? Check. Trump rhetoric on North Korea and football players?...

Logo
318 Views
Share
bearish•Celltrion Inc
•24 Sep 2017 03:44

Biosimilar Battlefield: Celltrion Forecasts

This Insight uses the biosimilar market model discussed inĀ Surveying The Biosimilar BattlefieldĀ to build a long-term revenue forecast for the...

Share
x